Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Asset Utilization Ratio: 2011-2025

Historic Asset Utilization Ratio for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Sep 2025 value amounting to 0.12.

  • Lineage Cell Therapeutics' Asset Utilization Ratio rose 37.08% to 0.12 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.12, marking a year-over-year increase of 37.08%. This contributed to the annual value of 0.09 for FY2024, which is 11.37% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Asset Utilization Ratio stood at 0.12, which was up 11.25% from 0.11 recorded in Q2 2025.
  • Lineage Cell Therapeutics' Asset Utilization Ratio's 5-year high stood at 0.47 during Q3 2022, with a 5-year trough of 0.01 in Q2 2021.
  • For the 3-year period, Lineage Cell Therapeutics' Asset Utilization Ratio averaged around 0.09, with its median value being 0.09 (2024).
  • Its Asset Utilization Ratio has fluctuated over the past 5 years, first surged by 3,078.23% in 2022, then slumped by 82.87% in 2023.
  • Lineage Cell Therapeutics' Asset Utilization Ratio (Quarterly) stood at 0.35 in 2021, then slumped by 66.82% to 0.12 in 2022, then decreased by 25.17% to 0.09 in 2023, then climbed by 4.86% to 0.09 in 2024, then soared by 37.08% to 0.12 in 2025.
  • Its Asset Utilization Ratio stands at 0.12 for Q3 2025, versus 0.11 for Q2 2025 and 0.08 for Q1 2025.